5KPK

Glycogen Synthase Kinase 3 beta Complexed with BRD0209

DOI: 10.2210/pdb5KPK/pdb

Classification: TRANSFERASE/TRANSFERASE INHIBITOR
Organism(s): Homo sapiens
Expression System: Spodoptera frugiperda
Mutation(s): No

Deposited: 2016-07-04 Released: 2018-03-14
Deposition Author(s): Lakshminarasimhan, D., White, A., Nadupalli, A., Suto, R.K.

Experimental Data Snapshot

Method: X-RAY DIFFRACTION
Resolution: 2.40 Å
R-Value Free: 0.224
R-Value Work: 0.167
R-Value Observed: 0.170

wwPDB Validation 3D Report Full Report

This is version 1.1 of the entry. See complete history.

Literature

Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.

Wagner, F.F., Benajiba, L., Campbell, A.J., Weiwer, M., Sacher, J.R., Gale, J.P., Ross, L., Puissant, A., Alexe, G., Conway, A., Back, M., Pikman, Y., Galinsky, I., DeAngelo, D.J., Stone, R.M., Kaya, T., Shi, X., Robers, M.B., Machleidt, T., Wilkinson, J., Hermine, O., Kung, A., Stein, A.J., Lakshminarasimhan, D., Hemann, M.T., Scolnick, E., Zhang, Y.L., Pan, J.Q., Stegmaier, K., Holson, E.B.

(2018) Sci Transl Med 10

PubMed: 29515000 Search on PubMedSearch on PubMed Central
DOI: 10.1126/scitranslmed.aam8460
Primary Citation of Related Structures:
5T31, 5KPK, 5KPM, 5KPL

PubMed Abstract:

Glycogen synthase kinase 3 (GSK3), a key regulatory kinase in the wingless-type MMTV integration site family (WNT) pathway, is a therapeutic target of interest in many diseases. Although dual GSK3α/β inhibitors have entered clinical trials, none has successfully translated to clinical application. Mechanism-based toxicities, driven in part by the inhibition of both GSK3 paralogs and subsequent β-catenin stabilization, are a concern in the translation of this target class because mutations and overexpression of β-catenin are associated with many cancers. Knockdown of GSK3α or GSK3β individually does not increase β-catenin and offers a conceptual resolution to targeting GSK3: paralog-selective inhibition. However, inadequate chemical tools exist. The design of selective adenosine triphosphate (ATP)-competitive inhibitors poses a drug discovery challenge due to the high homology (95% identity and 100% similarity) in this binding domain. Taking advantage of an Asp ¹³³→Glu ¹⁹⁶ "switch" in their kinase hinge, we present a rational design strategy toward the discovery of paralog-selective GSK3 inhibitors. These GSK3α- and GSK3β-selective inhibitors provide insights into GSK3 targeting in acute myeloid leukemia (AML), where GSK3α was identified as a therapeutic target using genetic approaches. The GSK3α-selective compound BRD0705 inhibits kinase function and does not stabilize β-catenin, mitigating potential neoplastic concerns. BRD0705 induces myeloid differentiation and impairs colony formation in AML cells, with no apparent effect on normal hematopoietic cells. Moreover, BRD0705 impairs leukemia initiation and prolongs survival in AML mouse models. These studies demonstrate feasibility of paralog-selective GSK3α inhibition, offering a promising therapeutic approach in AML.

Organizational Affiliation:

Stanley Center for Psychiatric Research, Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.

Macromolecules

Find similar proteins by:

(by identity cutoff) | Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Glycogen synthase kinase-3 beta	A, B	424	Homo sapiens	Mutation(s): 0 Gene Names: GSK3B EC: 2.7.11.26 (PDB Primary Data), 2.7.11.1 (PDB Primary Data)
Find proteins for P49841 (Homo sapiens) Explore P49841 Go to UniProtKB: P49841
NIH Common Fund Data Resources
PHAROS P49841 GTEx ENSG00000082701
Protein Feature View Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram	3D Interactions
6VK Query on 6VK Download Ideal Coordinates CCD File SDF format, chain C [A] SDF format, chain D [B] MOL2 format, chain C [A] MOL2 format, chain D [B]	A, B	(4~{S})-3-cyclopropyl-4,7,7-trimethyl-4-phenyl-2,6,8,9-tetrahydropyrazolo[3,4-b]quinolin-5-one C₂₂ H₂₅ N₃ O YKPIWOGXCSQLFH-JOCHJYFZSA-N		Ligand Interaction